Drug recall · October 18, 2023
BREXAFEMME recall
Why: Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04
- Lots / codes
Lot# LF21000008, Exp. 11/30/2023 Lot# LF22000051, Exp. 11/30/2025
- Quantity
- 17,376
- Company
- Scynexis, Inc., Jersey City, NJ
- Distribution
- Nationwide in the US.
- Initiated
- September 25, 2023 · Voluntary: Firm initiated
- Classified
- October 6, 2023
- Reported
- October 18, 2023
- How notified
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.